Journey Medical Corporation

NCM: DERM
Live Quote

📈 ZcoreAI Score

Our AI model analyzes Journey Medical Corporation's price action across multiple timeframes using regression channels and statistical scoring.

Get DERM Z-Score →

About Journey Medical Corporation

Healthcare Drug Manufacturers - Specialty & Generic
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

📊 Fundamental Analysis

Journey Medical Corporation demonstrates a profit margin of -18.5%, which is below the sector average, suggesting competitive pressure.

The company recently reported 18.1% revenue growth, which is well above average for the Healthcare sector.

Return on Equity (ROE) is -44.0%, which indicates that capital utilization is currently under pressure.

At a current price of $5.17, DERM currently trades near the bottom of its 52-week range (16%), indicating potential value or weakness (Range: $4.31 - $9.55).

🏥 Financial Health

🔴 Profit Margin Weak
🔴 Debt/Equity Elevated
Revenue Growth Excellent
🔴 Return on Equity Weak
⚠️ Beta (Risk) Moderate Volatility

Key Financials

Market Cap
$171.94M
Trailing P/E
--
Forward P/E
-86.17
Beta (5Y)
1.04
52W High
$9.55
52W Low
$4.31
Avg Volume
205K
Day High
Day Low
Get DERM Z-Score on Dashboard 🚀